Business Standard Lupin is betting big on dermatology, asthma care and ophthalmology to drive future growth. In this regard, it is expected to launch Gatifloxacin (anti-biotic) eye drops in the current quarter. Analysts estimate around $20 million to be added to the ... and more »
The Star Online On the downside, his “diet” of pills to keep other diseases at bay has increased, with the “menu” now consisting of Fenofibrate to manage triglycerides, Perindopril Erbumine (ACE inhibitor); Pravastatin to reduce lipids; Amlodipine for high blood ...
